USPTO serial 79169309
ADLIB
Reviewed by CopyMark Law Group
Reg. 5139363Status 707Renewal
- Filing date
- Status date
- Registration date
- Feb 14, 2017
- Examiner
- MAHONEY, PAULA M
- Law office
- —
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with ADLIB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jeffrey H. Handelsman
Jeffrey H. Handelsman Greenblum & Bernstein, P.L.C.1950 Roland Clarke PlaceReston, VA 20191-1411UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ Monoclonal antibodies for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; peptides and proteins for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; biological and chemical preparations and reagents for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicines for human purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicines for dental purposes, namely, for infectious diseases, neurological diseases or inflammatory diseases; medicines for veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicinal preparations, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; living cells for manufacturing monoclonal antibodies used for medical purposes; cell lines for manufacturing monoclonal antibodies used for medical purposes; living cells for manufacturing monoclonal antibodies used for veterinary purposes; cell lines for manufacturing monoclonal antibodies used for veterinary purposes; biological tissue cultures for medical purposes, namely, for cultivating living cells or cell lines used for manufacturing monoclonal antibodies; surgical implants comprised of living tissues; biological implants, namely, a vital processed human or animal connective tissue; disinfectants for hygiene purposes; sanitary sterilising preparations; biocides; preparations for destroying vermin ] | SECTION 71 - CANCELLED | — |
| 042 | [ Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; design and development of medical technology; research and development in the field of biotechnology; pharmaceutical research and development; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use with medical technology; software design and development; providing temporary use of non-downloadable business software; rental of computer software; cloud computing featuring software used for development of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products ] * Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; [ design and development of medical technology; ] research and development in the field of biotechnology; pharmaceutical research and development; [ conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; ] technical project studies in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; research and development of new products for others [ ; design and development of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; providing temporary use of non-downloadable business software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; rental of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; cloud computing featuring software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals * ] | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Chiome Bioscience Inc.
- Other trademarks owned by Chiome Bioscience Inc.
- Other trademarks owned by Chiome Bioscience Inc.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ADLIB
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 15, 2026 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Apr 24, 2025 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Apr 18, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 1, 2024 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Feb 26, 2024 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Feb 26, 2024 | INPC | INVALIDATION PROCESSED | — |
| Feb 10, 2024 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jun 10, 2023 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Jun 10, 2023 | 71.P | REGISTERED - PARTIAL SEC 71 ACCEPTED | — |
| May 29, 2023 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Nov 15, 2022 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Feb 14, 2022 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Mar 7, 2018 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Feb 23, 2018 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Oct 28, 2017 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 15, 2017 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 15, 2017 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 4, 2017 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jun 23, 2017 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Jun 6, 2017 | PLGL | ASSIGNED TO PARALEGAL | — |
| May 14, 2017 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 9, 2017 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Feb 14, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 1, 2017 | CHPN | POST PUBLICATION AMENDMENT – NOT ENTERED | — |
| Jan 31, 2017 | APET | ASSIGNED TO PETITION STAFF | — |
| Dec 28, 2016 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 28, 2016 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Dec 16, 2016 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 16, 2016 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Nov 29, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 29, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 9, 2016 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 9, 2016 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Nov 9, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 27, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 13, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 24, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 23, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 23, 2016 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Sep 19, 2016 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Sep 15, 2016 | ALIE | ASSIGNED TO LIE | — |
| Mar 10, 2016 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Mar 10, 2016 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Mar 10, 2016 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 16, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 15, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 15, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 15, 2016 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 15, 2016 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 4, 2015 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 14, 2015 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 14, 2015 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 14, 2015 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 13, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 8, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 29, 2015 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 25, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 23, 2015 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |